Considering that most patients (approximately 89%) enrolled in the DESTINY-Breast04 trial were ER-positive, this new targeted agent could be a promising alternative in patients with ER-positive, HER2 IHC 2+ breast cancer. Here, ESR1 is linked to breast carcinoma.